Works by Yap, Timothy A.


Results: 126
    1
    2
    3

    First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 13, p. 1, doi. 10.1002/cncr.35939
    By:
    • Yap, Timothy A.;
    • Rixe, Olivier;
    • Baldini, Capucine;
    • Brown‐Glaberman, Ursa;
    • Efuni, Sergey;
    • Hong, David S.;
    • Massard, Christophe;
    • Muzaffar, Jameel;
    • Varga, Andreea;
    • Yilmaz, Emrullah;
    • Ikawa, Yuta;
    • Shiue, Lisa H.;
    • Liu, Yi;
    • Hruska, Matthew W.;
    • Zhao, Henry;
    • Tokunaga, Akihiro;
    • Sahebjam, Solmaz
    Publication type:
    Article
    4

    Charting New Frontiers.

    Published in:
    2011
    By:
    • Hee Jia Yun;
    • Fan Jing Jing;
    • Looi Qin En;
    • Timothy Yap Shi-Jie;
    • Wen Qianlin
    Publication type:
    Proceeding
    5
    6
    7
    8
    9
    10
    11
    12

    First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors.

    Published in:
    Oncologist, 2021, v. 26, n. 11, p. 925, doi. 10.1002/onco.13911
    By:
    • Do, Khanh T.;
    • Chow, Laura Quan Man;
    • Reckamp, Karen;
    • Sanborn, Rachel E.;
    • Burris, Howard;
    • Robert, Francisco;
    • Camidge, D. Ross;
    • Steuer, Conor E.;
    • Strickler, John H.;
    • Weise, Amy;
    • Specht, Jennifer M.;
    • Gutierrez, Martin;
    • Haughney, Peter;
    • Hengel, Shawna;
    • Derleth, Christina Louise;
    • Yap, Timothy A.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
    By:
    • Piha-Paul, Sarina A.;
    • Tseng, Chieh;
    • Tran, Hai T.;
    • Gao, Meng;
    • Karp, Daniel D.;
    • Subbiah, Vivek;
    • Tsimberidou, Apostolia Maria;
    • Kawedia, Jitesh D.;
    • Fu, Siqing;
    • Pant, Shubham;
    • Yap, Timothy A.;
    • Morris, Van K.;
    • Kee, Bryan K.;
    • Blum Murphy, Mariela;
    • Lim, JoAnn;
    • Meric-Bernstam, Funda
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16588-3
    By:
    • Mendoza, Tito R.;
    • Hong, David S.;
    • Peterson, Christine B.;
    • Stephen, Bettzy;
    • Dumbrava, Ecaterina;
    • Pant, Shubbam;
    • Tsimberidou, Apostolia Maria;
    • Yap, Timothy Anthony;
    • Sheshadri, Ajay;
    • Altan, Mehmet;
    • George, Goldy;
    • Castillo, Lilibeth;
    • Rodriguez, Enedelia;
    • Gong, Jing;
    • Subbiah, Vivek;
    • Janku, Filip;
    • Fu, Siqing;
    • Piha-Paul, Sarina A.;
    • Ahnert, Jordi Rodon;
    • Karp, Daniel D.
    Publication type:
    Article
    43
    44
    45
    46
    47
    48

    Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
    By:
    • Knisely, Anne;
    • Ahmed, Jibran;
    • Stephen, Bettzy;
    • Piha‐Paul, Sarina A.;
    • Karp, Daniel;
    • Zarifa, Abdulrazzak;
    • Fu, Siqing;
    • Hong, David Sanghyun;
    • Rodon Ahnert, Jordi;
    • Yap, Timothy A.;
    • Tsimberidou, Apostolia M.;
    • Alshawa, Anas;
    • Dumbrava, Ecaterina E.;
    • Yang, Yali;
    • Song, Juhee;
    • Meric‐Bernstam, Funda;
    • Jazaeri, Amir A.;
    • Naing, Aung
    Publication type:
    Article
    49
    50